HC Wainwright Reiterates Buy Rating on Monopar Therapeutics
HC Wainwright maintains its buy rating for Monopar Therapeutics with a $105 price target, a 13.40% upside from the current price.
Key Points
- On June 29, 2026, HC Wainwright reiterated its buy rating on Monopar Therapeutics, setting a $105 price target.
- HC Wainwright's $105 price target implies 13.40% upside from Monopar Therapeutics Inc.'s ($MNPR) current $92.59 share price.
- Shares of Monopar Therapeutics traded near $94.56 on Wednesday, with a market cap of approximately $620.3 million.
- Insiders have been actively buying, and analysts maintain a strong buy consensus with a mean target price of $112.62.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 29, 2026, HC Wainwright reiterated its buy rating for Monopar Therapeutics Inc. (NasdaqCM:MNPR), setting a price target of $105. This decision reflects the firm's continued confidence in Monopar's potential.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Monopar Therapeutics Inc. Stock Down 17.2%
Shares of Monopar Therapeutics traded near $94.56 on Wednesday. The company, which operates in the biotechnology sector, has a market cap of about $620.3 million. Although it has no meaningful P/E ratio due to its lack of profitability, Monopar's stock has shown volatility with a 52-week range between $29.18 and $105.0. The stock's 50-day moving average is $62.52, while the 200-day moving average stands at $67.90. Monopar maintains a strong liquidity position with a current ratio of 56.05 and a quick ratio of 55.94.
$MNPR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 29, 2026, HC Wainwright & Co. reiterated its buy rating for Monopar Therapeutics with a $105 price target. The day before, on June 30, BTIG maintained its buy rating with a higher target of $117. Chardan Capital also maintained its buy rating earlier in the year, setting a target of $100. Overall, the consensus among analysts is a strong buy, with a mean target price of $112.62 based on 13 opinions.
Insider Buying and Selling at Monopar Therapeutics Inc.
Recent insider activity at Monopar Therapeutics shows a trend towards buying. Notably, on June 26, 2026, Nicole Sweeny purchased 1,284 shares. Earlier in the year, on March 2, Susan Rodriguez, the Chief Commercial Strategy Officer, acquired 48,728 shares. CEO Chandler Robinson also made a significant purchase of 62,815 shares on January 28, 2025.
Other Institutional Activity in Monopar Therapeutics
Several institutional investors have adjusted their positions in Monopar Therapeutics. Saturn V Capital Management LP increased its holdings by 19,925 shares, ending with 345,626 shares valued at about $18.9 million. Deerfield Management Company, L.P. made a significant move by adding 153,187 shares, resulting in a total of 323,745 shares worth approximately $17.7 million. BlackRock, Inc. also boosted its stake by 61,710 shares to hold 316,567 shares valued at $17.3 million. Conversely, Adage Capital Partners GP, L.L.C. reduced its position by 330,272 shares, bringing its total to 309,195 shares worth $16.9 million.
About Monopar Therapeutics
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Wilmette, Illinois. It focuses on developing treatments for cancer. The company's pipeline includes MNPR-101, a monoclonal antibody for treating advanced solid tumors, and ALXN1840, a drug candidate for Wilson disease. Under the leadership of CEO Dr. Chandler D. Robinson, Monopar collaborates with partners such as NorthStar and Excel Diagnostics to advance its therapeutic and diagnostic solutions.
Bottom Line
Monopar Therapeutics continues to attract attention from analysts and investors alike. With HC Wainwright reiterating its buy rating and setting a $105 target, the company maintains a strong position in the biotechnology sector. While insider buying suggests confidence in the company's future, it's important to remember that 13F filings and analyst ratings are backward-looking and do not necessarily indicate future performance.
Get Monopar Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $MNPR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.